Connaughton Bernadette 4

What Happened

• Bernadette Connaughton, a director of Halozyme Therapeutics, received two grants on May 5, 2026: 6,796 restricted stock units (RSUs) and 6,040 stock options (reported as a derivative grant). Both grants show an acquisition price of $0 (these are compensation awards, not cash purchases).

Key Details

• Transaction date: May 5, 2026; Form 4 filed May 7, 2026 (filed within the typical 2‑business‑day window).
• Counts and price: 6,796 RSUs @ $0; 6,040 option units (derivative) @ $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — RSUs: each RSU converts to one share; vest in full on the earlier of May 5, 2027 or the issuer’s next annual meeting. F2 — stock option grant: vests on the same schedule (earlier of May 5, 2027 or next annual meeting).
• Transaction code: A = grant/award; the option grant is reported as a derivative security.

Context

• These awards are routine director compensation (non-cash) and will vest in the future per the stated schedule; they are not exercises or immediate sales. RSUs represent a right to receive shares when vested; options will require a future exercise to convert to shares. Such grants increase potential future dilution but do not by themselves indicate an immediate buy or sell decision.